Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support

Leuk Lymphoma. 2016;57(6):1482-6. doi: 10.3109/10428194.2015.1099648. Epub 2015 Nov 16.

Affiliations

¹ a Department of Internal Medicine I , University Hospital of Schleswig-Holstein , Luebeck , Germany ;
² b Department of Pathology , Reference Centre for Lymph Node Pathology and Hematopathology, University Hospital of Schleswig-Holstein , Luebeck , Germany ;
³ c Department of Radiation Oncology , University Hospital of Schleswig-Holstein , Luebeck , Germany.

PMID: 26414189
DOI: 10.3109/10428194.2015.1099648

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents, Alkylating / therapeutic use
Hematopoietic Stem Cell Transplantation
Humans
Kaplan-Meier Estimate
Melphalan / therapeutic use
Multiple Myeloma / genetics*
Multiple Myeloma / mortality*
Multiple Myeloma / therapy
Polymorphism, Single Nucleotide*
Prognosis
Proto-Oncogene Proteins c-mdm2 / genetics*
Proto-Oncogene Proteins p21(ras) / genetics*
Transplantation, Autologous
Treatment Outcome
Tumor Suppressor Protein p53 / genetics*

Substances

Antineoplastic Agents, Alkylating
Tumor Suppressor Protein p53
Proto-Oncogene Proteins c-mdm2
Proto-Oncogene Proteins p21(ras)
Melphalan